Land: Irland
Språk: engelsk
Kilde: HPRA (Health Products Regulatory Authority)
Paricalcitol
AbbVie Limited
H05BX; H05BX02
Paricalcitol
2 microgram(s)
Capsule, soft
Product subject to prescription which may be renewed (B)
Other anti-parathyroid agents; paricalcitol
Marketed
2008-01-25
1 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT ZEMPLAR 1 MICROGRAM CAPSULES, SOFT ZEMPLAR 2 MICROGRAMS CAPSULES, SOFT paricalcitol READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Zemplar is and what it is used for 2. What you need to know before you take Zemplar 3. How to take Zemplar 4. Possible side effects 5. How to store Zemplar 6. Contents of the pack and other information 1. WHAT ZEMPLAR IS AND WHAT IT IS USED FOR Zemplar contains the active substance paricalcitol, which is a synthetic form of active vitamin D. Active vitamin D is required for the normal functioning of many tissues in the body, including the parathyroid gland and bones. In people who have normal kidney function, this active form of vitamin D is naturally produced by the kidneys, but in kidney failure the production of active vitamin D is markedly reduced. Zemplar therefore provides a source of active vitamin D, when the body cannot produce enough and helps to prevent the consequences of low levels of active vitamin D, namely high levels of parathyroid hormone which can cause bone problems. Zemplar is used in adult patients with kidney disease Stages 3, 4 and 5 and children aged 10 to 16 years with kidney disease Stages 3 and 4. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ZEMPLAR DO NOT TAKE ZEMPLAR - if you are allergic to paricalcitol or any of the other ingredients of this medicine (listed in section 6). - if you have very high levels of calcium or vitamin D in your blood. Your doctor will be able to tell you if these condi read_full_document
Health Products Regulatory Authority 04 November 2022 CRN00D0D2 Page 1 of 11 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zemplar 2 micrograms capsules, soft 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule of Zemplar 2 microgram contains 2 microgram of paricalcitol. Excipient with known effect: Each capsule of Zemplar 2 microgram contains 1.42 mg of ethanol. For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Capsule, soft 2 micrograms capsule: oval, orange-brown soft capsule imprinted with ZF 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Zemplar is indicated in adult and paediatric patients 10 to 16 years of age for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease Stages 3 and 4. Zemplar is indicated in adult patients for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease Stage 5 in patients who are on haemodialysis or peritoneal dialysis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology CHRONIC KIDNEY DISEASE (CKD) STAGES 3 AND 4 Zemplar should be administered once a day, either daily or three times a week taken every other day. INITIAL DOSE The initial dose is based on baseline intact parathyroid hormone (iPTH) levels. TABLE 1. INITIAL DOSE BASELINE IPTH LEVEL DAILY DOSE THREE TIMES A WEEK DOSE * ≤ 500 pg/ml (56 pmol/l) 1 microgram 2 micrograms > 500 pg/ml (56 pmol/l) 2 micrograms 4 micrograms Health Products Regulatory Authority 04 November 2022 CRN00D0D2 Page 2 of 11 * TO BE ADMINISTERED NO MORE FREQUENTLY THAN EVERY OTHER DAY DOSE TITRATION Dosing must be individualised based on serum or plasma iPTH levels, with monitoring of serum calcium and serum phosphorus. Table 2 presents a suggested approach for dose titration. TABLE 2. DOSE TITRATION IPTH LEVEL RELATIVE TO BASELINE DOSE ADJUSTMENT AT 2 TO 4 WEEK INTERVALS DAILY DOSE THREE TIMES A WEEK DOSE 1 The same or increased Increase 1 microgram Increase 2 micrograms Decreased by read_full_document